Karyopharm reports Q3 EPS ($3.82), consensus ($3.25)

Reports Q3 revenue $44.0M, consensus $42.41M. Prior to the receipt of approximately $32M of net proceeds from the financing transactions announced by the Company on October 8, cash, cash equivalents, restricted cash and investments as of September 30, totaled $46.2M, compared to $109.1M as of December 31, 2024. “This has been a very productive quarter as we have strengthened our financial foundation and made meaningful clinical progress with enrollment completion of our Phase 3 SENTRY trial in myelofibrosis, marking a pivotal milestone for Karyopharm (KPTI),” said Richard Paulson, President and CEO of Karyopharm. “With SENTRY enrollment complete, our teams remain focused on clinical trial execution, preparing for top-line data in March, potential regulatory filings, and commercial launch readiness, as we work to redefine the standard-of-care for frontline myelofibrosis patients, pending regulatory approvals.”